Shilajit and Male Fertility, What the Sperm Health Research Actually Shows
One clinical study is the entire human sperm-count evidence base for shilajit, and it found something worth taking seriously. In a 90 day open-label trial, 35 men with diagnosed low sperm counts saw their counts rise by an average of 61 percent, motility improve, and testosterone climb 23.5 percent, while a marker of oxidative damage in their semen fell by nearly a fifth. No placebo arm, no blinding, one paper. Here is exactly what it found, what it did not, and the mechanism that would explain it if it holds up.
What did the sperm count study actually measure?
Biswas and colleagues published the trial in 2010. Thirty-five men, all already diagnosed with oligospermia, a clinical term for a lower-than-normal sperm count, took a standardized shilajit preparation for 90 days. Nobody in the study was a fertile control. Every man enrolled had a real, documented problem.
The results, measured before and after the 90 days:
- Sperm count rose by an average of 61 percent
- Sperm motility, the percentage moving normally, improved by 12 to 17 percent
- Total testosterone rose 23.5 percent
- A marker of oxidative stress in the semen fell 18.7 percent
- No changes in liver or kidney function markers were reported
Why "open-label" matters more than the headline number
An open-label design means every man knew what he was taking. There was no placebo group swallowing an identical-looking capsule with nothing in it, and no blinding to control for expectation effects. That is the single biggest asterisk on this data, and it is the reason we will not tell you shilajit is a proven fertility treatment. It is one open-label study, and the honest reading is a promising signal, not a verdict.
Why does oxidative stress connect all three results?
Sperm cells have an unusual vulnerability. Their membranes are packed with polyunsaturated fats, the same kind of fat that goes rancid fastest in a kitchen, and the cell has very limited antioxidant machinery of its own to protect that fat once it is under attack. Oxidative stress, an excess of unstable molecules relative to the cell's ability to neutralize them, is one of the most consistently identified factors in unexplained male infertility.
That is the backdrop the Biswas study's third finding sits against. The 18.7 percent drop in an oxidative-stress marker is not a side observation. It is the plausible reason the other two numbers moved at all, since a sperm cell under less oxidative attack has a better chance of surviving to maturity and of swimming normally once it gets there.
Shilajit's fulvic acid fraction is the component researchers point to for this antioxidant action. It is the same broad mechanism behind shilajit's studied effect on oxidative markers in unrelated human trials, including the 48 week bone study in postmenopausal women, where fulvic acid's antioxidant behavior showed up again in a completely different tissue.
How does this differ from testosterone replacement therapy?
A separate 2016 trial by Pandit and colleagues, run in healthy men aged 45 to 55 rather than men with fertility problems, offers a second data point on the testosterone side and a useful contrast with TRT.
| Testosterone replacement therapy | Shilajit (Pandit 2016) | |
|---|---|---|
| How it works | Delivers testosterone directly into the bloodstream | Appears to support the body's own production |
| Effect on total testosterone | Raises it, often substantially | Rose 20.45 percent over 90 days |
| Effect on LH and FSH | Typically suppressed, since the brain senses enough T is already present | Maintained, not suppressed |
| What that means | Natural production can slow or stop while on therapy | The signal telling the testicles to keep producing stays intact |
LH and FSH are the pituitary hormones that instruct the testicles to keep making testosterone. When an outside source floods the system, as TRT does by design, the brain often dials that signal down. The Pandit trial found testosterone rose in the shilajit group while LH and FSH held steady, which is a mechanistically different picture than injecting hormone from outside the system.
Neither trial was run in infertile men taking shilajit specifically to raise testosterone for conception, so this comparison is mechanism, not a fertility-outcome claim on its own.
Where does the fertility evidence stop?
We would rather tell you the ceiling plainly than have a doctor point it out for us.
No placebo-controlled human trial has tested shilajit against male infertility. The Biswas study is the only human sperm-count data shilajit has, it ran in 35 men, it had no control group, and 90 days is not a long observation window for a condition that can take months to resolve on its own. A single open-label study, however promising, is not the same as proof.
- The 61 percent count figure came from before-and-after comparison within one group, not against a placebo arm
- The men studied already had a diagnosed low count, so this data does not describe what shilajit does to a normal sperm count
- The oxidative-stress mechanism is well established in the broader fertility literature, but the direct shilajit-sperm link rests on this one trial
- The testosterone comparison with Pandit 2016 came from a different, non-infertile population
- No study has tracked live birth or pregnancy rates with shilajit as the variable
How does shilajit fit into a fertility-support routine?
Shilajit is not a fertility drug, and nothing here should replace a fertility workup with a physician if a couple is actively trying to conceive and running into difficulty. What the research supports is narrower and still useful. It is a mineral- and fulvic-acid-rich compound that, in one clinical study of men with low counts, moved in the direction that matters, count, motility, and the oxidative environment sperm develop in.
Across the human shilajit studies on file, including this one, no serious adverse events or organ-function changes have been reported. Sourced from the Altai mountains, purified, and lab tested for heavy metals on every batch, with the report published for anyone to read, Optimum Shilajit is the product built around this research.
Common questions about shilajit and male fertility
Does shilajit actually raise sperm count?
One clinical study found it does. Biswas and colleagues ran a 90 day trial in 35 men already diagnosed with low sperm count and found a 61 percent average rise, alongside gains in motility and a drop in oxidative stress markers in the semen. It is one study, not a settled fact, and we say so throughout this piece.
Was the sperm study placebo-controlled?
No. It was open-label, meaning every man in the study knew he was taking shilajit and there was no dummy-pill comparison group. That is the single biggest limitation of the evidence, and it means the real effect could be smaller than the 61 percent figure once a placebo-controlled trial is run.
How is this different from testosterone replacement therapy?
TRT delivers testosterone directly, which tells the brain the body already has enough and can shut down its own signal to the testicles. The Pandit 2016 trial found shilajit raised testosterone while LH and FSH, the pituitary signals that keep natural production running, stayed steady. It appears to support the system rather than override it.
Why would an antioxidant affect fertility at all?
Sperm cells carry very little internal antioxidant defense relative to how much oxidative damage their membranes are exposed to. Oxidative stress is one of the most common findings in unexplained male infertility. The oligospermia study measured a real drop in a semen oxidative-stress marker alongside the count and motility gains, which lines up with that mechanism.
Is shilajit safe for men trying to conceive?
Across the human shilajit studies on file, including this one, no liver or kidney toxicity and no serious adverse events have been reported. That is not the same as a large, dedicated fertility-safety trial, and any man on fertility medication or with a diagnosed condition should keep his physician informed of everything he takes.
Sources
- Biswas TK, et al. Clinical evaluation of spermatogenic activity of processed shilajit in oligospermia. Andrologia, 2010. https://pubmed.ncbi.nlm.nih.gov/20078516/
- Pandit S, et al. Clinical evaluation of purified shilajit on testosterone levels in healthy volunteers. Andrologia, 2016. https://pubmed.ncbi.nlm.nih.gov/26395129/
- Pingali U, et al. Effect of standardized shilajit on bone mineral density in postmenopausal women, a 48 week double blind randomized controlled trial. 2022. https://pubmed.ncbi.nlm.nih.gov/35933897/